Expert Interview
Discussing Palatin Technologies' Report of Positive Appetite Suppression Results in Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Ticker(s): PTNInstitution: Luminis Health
- More than a decade of experience in the field of endocrinology, with a focus on cardio metabolic outcomes, complex diabetes, obesity and transgender endocrinology.
- Treats over 900 patients per year with obesity.
- Subject matter expert and KEY OPINION LEADER on MC4R Agonist like Setmelanotide, tirzepatide and can discuss in depth.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
